UK Edition. Click here for US version.
BOOTS DIARRHOEA RELIEF 2MG CAPSULES
Active substance(s): LOPERAMIDE HYDROCHLORIDE / LOPERAMIDE HYDROCHLORIDE / LOPERAMIDE HYDROCHLORIDE
NAME OF THE MEDICINAL PRODUCT
Value Health Diarrhoea Relief 2mg Capsules Boots Diarrhoea Relief 2mg Capsules
QUALITATIVE AND QUANTITATIVE COMPOSITION
Loperamide Hydrochloride 2 mg per capsule
Capsules, hard (Capsule) Hard, gelatine capsule (size 4) with an opaque green cap printed "0611" in black ink, and an opaque grey body containing a white powder.
Therapeutic indications P and GSL: For the symptomatic treatment of acute diarrhoea, in adults and children 12 years and over. For the symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome in adults aged 18 years and over following initial diagnosis by a doctor.
Posology and method of administration
The capsules should be taken with liquid. For oral administration. Acute diarrhoea: Adults and children of 12 years of age and over:
The initial dose is 2 capsules (4 mg) followed by 1 capsule (2 mg) after every subsequent loose stool. If symptoms persist for more than 24 hours consult your doctor. For the symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome in adults aged 18 years and over following initial diagnosis by a doctor: The initial dose is 2 capsules (4 mg). This initial dose should be adjusted until 1-2 solid stools a day are obtained, which is usually achieved with a maintenance dose of 1-6 capsules (2-12 mg) daily. Consult your doctor if you develop new symptoms, or if your symptoms worsen, or if your symptoms have not improved over two weeks. The maximum dose for acute diarrhoea and acute episodes of diarrhoea associated with irritable bowel is: GSL 6 capsules (12 mg) daily for adults and children of 12 years of age and over P 8 capsules (16 mg) daily for adults and children of 12 years of age and over Children under 12 years Loperamide HCl capsules should not be used in children under 12 years of age. Elderly No dose adjustment is required for the elderly. Renal impairment No dose adjustment is required for patients with renal impairment. Hepatic impairment Although no pharmacokinetic data are available in patients with hepatic impairment, loperamide HCl should be used with caution in such patients because of reduced first pass metabolism (see section 4.4 special warnings and special precautions for use).
Loperamide HCl is contraindicated in patients with known hypersensitivity to loperamide HCl or to any of the excipients. The loperamide HCl capsule should not be used in children under 12 years of age. Loperamide HCl should not be used as the primary therapy:
in patients with acute dysentery, which is characterised by blood in stools and high fever, in patients with acute ulcerative colitis, in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter, in patients with pseudomembranous colitis associated with the use of broad-spectrum antibiotics.
Loperamide HCl should not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon. Loperamide HCl must be discontinued promptly when constipation, abdominal distension or ileus develop.
Special warnings and precautions for use
Treatment of diarrhoea with loperamide HCl is only symptomatic. Whenever an underlying aetiology can be determined, specific treatment should be given when appropriate. In patients with diarrhoea, especially in children, frail and elderly patients, fluid and electrolyte depletion may occur. In such cases administration of appropriate fluid and electrolyte replacement therapy is the most important measure. In acute diarrhoea, if clinical improvement is not observed within 24 hours, the administration of loperamide HCl should be discontinued and patients should be advised to consult their physician. This product should not be used for prolonged periods. Diarrhoea is a common presentation of a number of significant gastrointestinal conditions. This medicine is indicated only for the symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome. This medicine should not be used for prolonged periods until an underlying cause for persistent diarrhoea has been investigated and diagnosed by a doctor. Patients with AIDS treated with loperamide HCl for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. There have been isolated reports of obstipation with an increased risk for toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide HCl. Although no pharmacokinetic data are available in patients with hepatic impairment, loperamide HCl should be used with caution in such patients because of reduced first pass metabolism. This medicine must be used with caution in patients with hepatic impairment as it may result in a relative overdose leading to CNS toxicity. For acute diarrhoea If symptoms persist for more than 24 hours, consult your doctor.
For acute episodes of diarrhoea associated with irritable bowel syndrome Warnings to be included in the leaflet: Only take loperamide HCl to treat acute episodes of diarrhoea associated with irritable bowel syndrome (IBS) if your doctor has previously diagnosed IBS. If any of the following now apply, do not use the product without first consulting your doctor, even if you know you have IBS: If you are 40 years or over and it is some time since your last attack of IBS or the symptoms are different this time
If you have recently passed blood from the bowel If you suffer from severe constipation If you are feeling sick or vomiting If you have lost your appetite or lost weight If you have difficulty or pain passing urine If you have a fever If you have recently travelled abroad Consult your doctor if you develop new symptoms, or if your symptoms worsen, or if your symptoms have not improved over two weeks. Keep all medicines out of the reach of children. Ponceau 4R (E124) can cause allergic-type reactions including asthma. Allergy is more common in those people who are allergic to aspirin.
Interaction with other medicinal products and other forms of interaction
Non-clinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with quinidine, or ritonavir, which are both P-glycoprotein inhibitors, resulted in a 2 to 3-fold increase in loperamide plasma levels. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors, when loperamide is given at recommended doses, is unknown. The concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 3 to 4-fold increase in loperamide plasma concentrations. In the same study a CYP2C8 inhibitor, gemfibrozil, increased loperamide by approximately 2-fold. The combination of itraconazole and gemfibrozil resulted in a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (i.e. subjective drowsiness and the Digit Symbol Substitution Test). The concomitant administration of loperamide (16 mg single dose) and ketoconazole,
an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. The increase was not associated with increased pharmacodynamic effects as measured by pupillometry. Concomitant treatment with oral desmopressin resulted in a 2-fold increase of desmopressin plasma concentrations, presumably due to slower gastrointestinal motility. It is expected that drugs with similar pharmacological properties may potentiate loperamides effect and that drugs that accelerate gastrointestinal transit may decrease its effect.
Pregnancy and lactation It is not advisable to administer this medicine in pregnancy. Women who are pregnant or breast feeding should therefore be advised to consult their doctor for appropriate treatment. Although there is no indication that loperamide HCl possesses teratogenic or embryotoxic properties it should not be administered in pregnancy. Small amounts of loperamide HCl may appear in human breast-milk. Therefore loperamide HCl is not recommended during breast-feeding.
Effects on ability to drive and use machines
Tiredness, dizziness or drowsiness may occur in the setting of diarrhoeal syndromes treated with loperamide HCl. Therefore, it is advisable to use caution when driving a car or operating machinery.
4.8 Undesirable effects Adults and children aged 12 years The safety of loperamide HCl was evaluated in 3076 adults and children aged 12 years who participated in 31 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of diarrhoea. Of these, 26 trials were in acute diarrhoea (N=2755) and 5 trials were in chronic diarrhoea (N=321). The most commonly reported (i.e. 1% incidence) adverse drug reactions (ADRs) in clinical trials with loperamide HCl in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%). In clinical trials in chronic diarrhoea, the most commonly reported (i.e. 1% incidence) ADRs were: flatulence (2.8%), constipation (2.2%), nausea (1.2%) and dizziness (1.2%).
Table 1 displays ADRs that have been reported with the use of loperamide HCl from either clinical trial (in acute or chronic diarrhoea or both) of post-marketing experience. The frequency categories use the following convention: very common (1/10); common (1/100 to <1/10); uncommon (1/1000 to <1/100); rare (1/10,000 to <1/1000); and very rare (<1/10,000). Table 1 Adverse Drug Reactions System Organ Class Indication Acute Diarrhoea (N=2755) Chronic Diarrhoea (N=321) Acute & Chronic Diarrhoea and post marketing experience
Immune System Disorders Hypersensitivity reactiona, Anaphylactic reaction (including Anaphylactic shock)a, Anaphylactoid reactiona Nervous System Disorders Headache Dizziness Somnolencea Loss of consciousnessa, Stupora, Depressed level of consciousness a, Hypertoniaa, Coordination abnormalitya Eye Disorders Miosisa Gastrointestinal Disorders Constipation, Nausea, Flatulence Abdominal pain, Abdominal discomfort, Dry mouth Abdominal pain upper, Vomiting Dyspepsia Ileusa (including paralytic ileus), Megacolona (including toxic megacolonb), Abdominal distension Skin and subcutaneous Tissue Disorders
Common Uncommon Common Uncommon Common Common Uncommon Rare
Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Rare Rare Rare
Rash Bullous eruptiona (including Stevens-Johnson syndrome, Toxic epidermal necrolysis and Erythema multiforme), Angioedemaa, Urticariaa, Pruritusa Renal and urinary disorders Urinary retentiona General Disorders and Administration Site Conditions Fatiguea
: Inclusion of this term is based on post-marketing reports for loperamide HCl. As the process for determining post marketing ADRs did not differentiate between chronic and acute indications for adults and children, the frequency is estimated from all clinical trials with loperamide HCl combined, including trials in children 12 years (N=3683). b : See section 4.4 Special Warnings and Special Precautions for use. For clinical trial ADRs where no frequency is presented, the term was not observed or considered an ADR for this indication. Paediatric population The safety of loperamide HCl was evaluated in 607 patients aged 10 days to 13 years who participated in 13 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of acute diarrhoea. In general, the ADR profile in this patient population was similar to that seen in clinical trials of loperamide HCl in adults and children aged 12 years and over. 4.9 Overdose
Symptoms In case of overdose (including relative overdose due to hepatic dysfunction), CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia, and respiratory depression), urinary retention, constipation and ileus may occur. Children may be more sensitive to CNS effects than adults. Treatment If symptoms of overdose occur, naloxone can be given as an antidote. Since the duration of action of loperamide is longer than that of naloxone (1 to 3 hours), repeated treatment with naloxone might be indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect possible CNS depression
Pharmacodynamic properties Loperamide hydrochloride is a synthetic opioid which inhibits gut motility by binding to opiate receptors in the gut wall and may also reduce gastrointestinal secretions, resulting in improvement in diarrhoeal symptoms. Loperamide also increases the tone of the anal sphincter. In a double blind randomised trial in 213 patients with acute diarrhoea, loperamide (56 patients) was compared with two other common antidiarrhoeal agents and placebo. Onset of antidiarrhoeal effect occurred as soon as one hour after intake of a 4mg dose of loperamide.
Pharmacokinetic properties More than 65% of a dose of loperamide is reported to be absorbed from the gastrointestinal tract. The drug undergoes considerable first pass metabolism in the liver and excretion via the bile in the faeces as the inactive conjugate. As a result of the drugs high affinity for the gut wall and its high first pass metabolism very little loperamide reaches the systemic circulation and therefore there is only a small amount of urinary excretion. The elimination half life is reported to be about 10 hours.
Preclinical safety data There are no preclinical data of relevance to the prescriber which are additional to that already included.
List of excipients
Lactose monohydrate Magnesium stearate
Maize starch (pregelatinised) Hard gelatin capsule (gelatin, Ponceau 4R-E124, Indigo Carmine-E132, Titanium dioxide-E171, Yellow and black iron oxides E172) Ink (Black iron oxide E172, Shellac, Propylene glycol)
Incompatibilities Not applicable.
Shelf life 36 months
Special precautions for storage Do not store above 30C. Store in the original package.
Nature and contents of container 1. Blister of clear 250 micron PVC and 20 micron aluminium foil. Pack size: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 48. 2. Blister of clear 250 micron PVC coated with 40 gsm PVdC and 20 micron aluminium foil. Pack size: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 48.
Instruction for use, handling and disposal Not applicable.
MARKETING AUTHORISATION HOLDER The Boots Company PLC 1 Thane Road West
Nottingham NG2 3AA Trading as Value Health 8. MARKETING AUTHORISATION NUMBER PL 00014/0611
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.